United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

Posted by George Bondi on Nov 4th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $596.22, for a total transaction of $5,664,090.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $193,439,405.46. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 0.9%

Shares of NASDAQ UTHR opened at $601.32 on Wednesday. The firm has a market cap of $25.79 billion, a price-to-earnings ratio of 21.51, a PEG ratio of 4.32 and a beta of 0.49. United Therapeutics Corporation has a 52-week low of $430.02 and a 52-week high of $609.99. The business’s 50 day moving average is $530.53 and its two-hundred day moving average is $531.77.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the prior year, the firm earned $6.41 earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 26.09 EPS for the current fiscal year.

United Therapeutics announced that its board has initiated a stock buyback plan on Thursday, October 22nd that permits the company to buy back $2 billion in outstanding shares. This repurchase authorization permits the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Institutional Trading of United Therapeutics

A number of large investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. lifted its position in United Therapeutics by 53.1% in the third quarter. University of Texas Texas AM Investment Management Co. now owns 14,282 shares of the biotechnology company’s stock valued at $7,739,000 after acquiring an additional 4,954 shares during the last quarter. Candriam S.C.A. grew its holdings in shares of United Therapeutics by 2.7% during the third quarter. Candriam S.C.A. now owns 55,109 shares of the biotechnology company’s stock worth $29,972,000 after purchasing an additional 1,425 shares during the last quarter. Ethic Inc. grew its holdings in shares of United Therapeutics by 60.0% during the third quarter. Ethic Inc. now owns 2,463 shares of the biotechnology company’s stock worth $1,335,000 after purchasing an additional 924 shares during the last quarter. StoneX Group Inc. purchased a new position in shares of United Therapeutics during the third quarter worth about $400,000. Finally, Parallel Advisors LLC increased its position in shares of United Therapeutics by 2.1% during the third quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock worth $625,000 after purchasing an additional 24 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of several research reports. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. UBS Group set a $725.00 price target on shares of United Therapeutics in a research note on Monday, October 19th. Raymond James Financial reissued an “outperform” rating and set a $717.00 price target on shares of United Therapeutics in a research report on Tuesday, October 20th. Leerink Partners raised their price objective on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Finally, Morgan Stanley raised their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $667.07.

Read Our Latest Analysis on UTHR

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.